Based on the selection criteria, seven studies were finally selected; in these studies, immunohistochemistry (IHC) was performed to determine EpCAM expression in patients with PCa [22, 23, 27, 33–36], (PCa tissue samples, n = 671; normal prostatic tissue samples, n = 30; benign prostatic tissue samples, n = 170). Here, EPCAM is linked to posterior cortical atrophy.